Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,goodWill,shortTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,MDG1.DE,21521000.0,24562700,5294500,,-7984500,,-8170500,1996000,1518500,-7316500,-7316500,1544500,-96000,,,,186000,2164500,9481000,646000,-668000,,-8170500,-8170500,31632000.0,21597000.0,53153000.0,8536000.0,74750000.0,24563000.0,286000.0,-451702000.0,7474000.0,480292000.0,287000.0,30033000.0,10131000.0,480292000.0,6882000.0,32695000.0,3254000.0,1960000.0,433000.0,,,10134500,-469500,10009000,-133000,-133000,-641000,5075500,-80500,-4720000,1511000,1000,1680000,1370000,-138500,22564000.0,en-US,US,EQUITY,False,Delayed Quote,3.885,1630575703,-0.07500005,3.885,3.89,3.885,210,EUR,GER,95426088,7200000,False,False,REGULAR,4,-1.8939406,3.885 - 3.89,de_market,0,MEDIGENE AG NA O.N.,3.96,3.875,3.92,579,1509,finmb_31320,XETRA,Medigene AG,EUR,15009,15536,0.67499995,0.21028036,3.21 - 5.1,-1.2149999,-0.23823528,3.21,5.1,1628765940,1628765940,1628765940,-1.176,-0.63,2.164,3.9522858,-0.067285776,-0.017024523,3.9498239,-0.064823866,-0.016411837,-6.1666665,1.7952864,15,Europe/Berlin,CEST,1.18,,,5.1,3.21,3.9523,3.9498,15.01k,15.54k,24.56M,,23.66M,10.38%,8.58%,,,,,,,,,,,0.00%,,,1:4,"Sep 03, 2013","Dec 31, 2020","Dec 31, 2020",0.00%,-339.86%,-18.48%,-42.79%,8M,0.33,-39.80%,6.71M,-23.82M,-28.88M,-1.1760,,30.03M,1.22,5.15M,9.70,3.23,2.16,-24.79M,-11.61M,Value,82152,Healthcare,114,7,8,"Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",Munich,49 89 2000 330,1,1609372800,1622505600,3,Germany,http://www.medigene.com,86400,3,Lochhamer Strasse 11,49 89 2000 3329 20,Biotechnology,Planegg/Martinsried
t-1,MDG1.DE,21521000.0,24562700,5294500,,-7984500,,-8170500,1996000,1518500,-7316500,-7316500,1544500,-96000,,,,186000,2164500,9481000,646000,-668000,,-8170500,-8170500,31632000.0,21597000.0,53153000.0,8536000.0,74750000.0,24563000.0,286000.0,-451702000.0,7474000.0,480292000.0,287000.0,30033000.0,10131000.0,480292000.0,6882000.0,32695000.0,3254000.0,1960000.0,433000.0,,,10134500,-469500,10009000,-133000,-133000,-641000,5075500,-80500,-4720000,1511000,1000,1680000,1370000,-138500,22564000.0,en-US,US,EQUITY,False,Delayed Quote,3.885,1630575703,-0.07500005,3.885,3.89,3.885,210,EUR,GER,95426088,7200000,False,False,REGULAR,4,-1.8939406,3.885 - 3.89,de_market,0,MEDIGENE AG NA O.N.,3.96,3.875,3.92,579,1509,finmb_31320,XETRA,Medigene AG,EUR,15009,15536,0.67499995,0.21028036,3.21 - 5.1,-1.2149999,-0.23823528,3.21,5.1,1628765940,1628765940,1628765940,-1.176,-0.63,2.164,3.9522858,-0.067285776,-0.017024523,3.9498239,-0.064823866,-0.016411837,-6.1666665,1.7952864,15,Europe/Berlin,CEST,1.18,,,5.1,3.21,3.9523,3.9498,15.01k,15.54k,24.56M,,23.66M,10.38%,8.58%,,,,,,,,,,,0.00%,,,1:4,"Sep 03, 2013","Dec 31, 2020","Dec 31, 2020",0.00%,-339.86%,-18.48%,-42.79%,8M,0.33,-39.80%,6.71M,-23.82M,-28.88M,-1.1760,,30.03M,1.22,5.15M,9.70,3.23,2.16,-24.79M,-11.61M,Value,82152,Healthcare,114,7,8,"Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",Munich,49 89 2000 330,1,1609372800,1622505600,3,Germany,http://www.medigene.com,86400,3,Lochhamer Strasse 11,49 89 2000 3329 20,Biotechnology,Planegg/Martinsried
t-2,MDG1.DE,33658000.0,24562700,5313000,,-5906000,,-5906000,2969000,2271000,-6010000,-6010000,-1000,-102000,,,,0,2271000,8281000,0,104000,,-5906000,-5906000,33472000.0,23760000.0,69342000.0,7917000.0,93102000.0,24563000.0,,-435361000.0,10089000.0,480140000.0,3405000.0,19882000.0,9575000.0,480140000.0,8065000.0,42602000.0,3346000.0,2720000.0,836000.0,2212000.0,20000000.0,153500,0,550000,-280000,-280000,-1645500,-7400000,3000,-7673000,619000,1000,-354500,-25000,-103500,33027000.0,en-US,US,EQUITY,False,Delayed Quote,3.885,1630575703,-0.07500005,3.885,3.89,3.885,210,EUR,GER,95426088,7200000,False,False,REGULAR,4,-1.8939406,3.885 - 3.89,de_market,0,MEDIGENE AG NA O.N.,3.96,3.875,3.92,579,1509,finmb_31320,XETRA,Medigene AG,EUR,15009,15536,0.67499995,0.21028036,3.21 - 5.1,-1.2149999,-0.23823528,3.21,5.1,1628765940,1628765940,1628765940,-1.176,-0.63,2.164,3.9522858,-0.067285776,-0.017024523,3.9498239,-0.064823866,-0.016411837,-6.1666665,1.7952864,15,Europe/Berlin,CEST,1.18,,,5.1,3.21,3.9523,3.9498,15.01k,15.54k,24.56M,,23.66M,10.38%,8.58%,,,,,,,,,,,0.00%,,,1:4,"Sep 03, 2013","Dec 31, 2020","Dec 31, 2020",0.00%,-339.86%,-18.48%,-42.79%,8M,0.33,-39.80%,6.71M,-23.82M,-28.88M,-1.1760,,30.03M,1.22,5.15M,9.70,3.23,2.16,-24.79M,-11.61M,Value,82152,Healthcare,114,7,8,"Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",Munich,49 89 2000 330,1,1609372800,1622505600,3,Germany,http://www.medigene.com,86400,3,Lochhamer Strasse 11,49 89 2000 3329 20,Biotechnology,Planegg/Martinsried
t-3,MDG1.DE,46120000.0,24562700,5836500,,-6217000,,-6267000,2282500,1836500,-6281500,-6281500,-1000,-103500,,,,50000,1836500,8118000,0,64500,,-6267000,-6267000,,,81823000.0,,,,,,,,,,,,,,,,,,,153500,0,550000,-280000,-280000,-1645500,-7400000,3000,-7673000,619000,1000,-354500,-25000,-103500,,en-US,US,EQUITY,False,Delayed Quote,3.885,1630575703,-0.07500005,3.885,3.89,3.885,210,EUR,GER,95426088,7200000,False,False,REGULAR,4,-1.8939406,3.885 - 3.89,de_market,0,MEDIGENE AG NA O.N.,3.96,3.875,3.92,579,1509,finmb_31320,XETRA,Medigene AG,EUR,15009,15536,0.67499995,0.21028036,3.21 - 5.1,-1.2149999,-0.23823528,3.21,5.1,1628765940,1628765940,1628765940,-1.176,-0.63,2.164,3.9522858,-0.067285776,-0.017024523,3.9498239,-0.064823866,-0.016411837,-6.1666665,1.7952864,15,Europe/Berlin,CEST,1.18,,,5.1,3.21,3.9523,3.9498,15.01k,15.54k,24.56M,,23.66M,10.38%,8.58%,,,,,,,,,,,0.00%,,,1:4,"Sep 03, 2013","Dec 31, 2020","Dec 31, 2020",0.00%,-339.86%,-18.48%,-42.79%,8M,0.33,-39.80%,6.71M,-23.82M,-28.88M,-1.1760,,30.03M,1.22,5.15M,9.70,3.23,2.16,-24.79M,-11.61M,Value,82152,Healthcare,114,7,8,"Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",Munich,49 89 2000 330,1,1609372800,1622505600,3,Germany,http://www.medigene.com,86400,3,Lochhamer Strasse 11,49 89 2000 3329 20,Biotechnology,Planegg/Martinsried
